NGFR and neoplasm: In accordance with the high-tumor burden setting, the antitumor effects of all three NGFR isoform-enriched CD44v6 CAR-T cells were accompanied by elevated systemic levels of human IFN-γ, in the absence of IL-6 and IL-10 (Figure 4E).